Trinity Biotech plc to Announce Q1 2024 Financial Results
Trinity Biotech (Nasdaq: TRIB), a company specializing in diabetes management solutions and human diagnostics, will release its Q1 2024 financial results on May 23, 2024, at 8:30 AM ET. The conference call will be accessible via dial-in and webcast, with specific numbers provided for the US and international participants. The webcast can be accessed through a given link.
- Announcement of Q1 2024 financial results indicates ongoing transparency and regular updates to shareholders.
- Scheduled conference call allows direct communication with investors and analysts, fostering engagement and trust.
- No preliminary financial data or performance highlights provided ahead of the announcement, leaving investors with uncertainty.
- Potential risks such as revenue declines or increased expenses not addressed in the PR.
Conference Call Scheduled for Thursday, May 23, 2024 at 8:30 AM ET.
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the first quarter 2024 on Thursday, May 23, 2024 at 8:30 AM ET.
Conference Call Dial-In & Webcast Information
| Date: | Thursday, May 23, 2024 |
| Time: | 8:30 AM ET |
| United States: | 1-877-407-0784 |
| International: | 1- 201-689-8560 |
| Conference ID: Webcast: Call me™: | 13746798 webcast link https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6 |
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com
| Contact: | Trinity Biotech plc | LifeSci Partners, LLC | ||
| Des Fitzgerald | Eric Ribner | |||
| (353)-1-2769800 | (1)-646-751-4363 | |||
| E-mail investorrelations@trinitybiotech.com |
FAQ
When will Trinity Biotech announce its Q1 2024 financial results?
How can I access Trinity Biotech's Q1 2024 financial results conference call?
What is the stock symbol for Trinity Biotech?
